Why You Should Attend

  • To know how leading Pharma is implementing AI in its operations and what the implications are for early assessment of DDIs as well as faster evaluations during drug development,

  • To become familiar with the role of automation/robotics in getting in vitro data related to DDIs, and how these fit to various types of in vitro NAM systems,

  • To expand your knowledge of DDIs related to “Non-Small Molecular” drug entities that may need specific considerations,

  • To get an update on transporter-related DDIs and expectations regarding understanding of the interactions of your compound with transporters in health and disease,

  • To see the latest outcomes from the debates on assessing transporter-related DDIs as the ICH guidelines gets implemented and regulatory expectations become clearer,

  • To update yourself on practical aspects of considering DDIs during Phase III studies and implications for inclusion/exclusion criteria and patient recruitment,

  • To understand how results on DDIs are translated into label language in order to support avoiding and/or proper handling of DDIs in patients,

  • To discuss case-studies of complex DDIs and the role of M&S in resolving key questions when dealing with regulatory submissions,

  • To reflect on the role of PBPK for assessing DDIs related to new modalities and experience with case examples how to quantify and manage such DDIs,

… and most importantly,

  • To network with a unique group of key opinion leaders from around the World on key issues related to DDIs, from scientific assessment to practical applications in drug development, and clinical practice.